Skip to main content
Erschienen in:

01.07.2008 | Leitthema

Übertherapie in der Onkologie: Wann ist weniger mehr?

verfasst von: Dr. U. Wedding, J.G. Meran, K. Höffken

Erschienen in: Die Onkologie | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

Es liegen nur wenige systematische Daten vor, die untersuchen, inwieweit in der Versorgung onkologischer Patienten in Deutschland eine Überbehandlung stattfindet. Überbehandlung wird in der Onkologie bewusst im Bereich der adjuvanten Therapie in Kauf genommen. Der Behandlungsvorteil einiger Patienten rechtfertigt hier die Therapie vieler Patienten. Aufgabe zukünftiger Studien ist es, diejenigen Patienten besser zu identifizieren, die von einer Therapie profitieren. Im Bereich der Behandlung mit nichtkurativem Ziel werden in Dritt-, Viert- oder Fünftlinien-Chemotherapien häufig wissenschaftlich nicht begründete Hoffnungen gelegt. Eine autonome Entscheidung seitens des Patienten setzt hier die Kenntnis palliativmedizinischer Behandlungsmöglichkeiten voraus.
Literatur
1.
Zurück zum Zitat (1998) Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Italian Group for Antiemetic Research. Ann Oncol 9: 759–765 (1998) Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Italian Group for Antiemetic Research. Ann Oncol 9: 759–765
2.
Zurück zum Zitat Early Breast Cancer Trialists‘ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717CrossRef Early Breast Cancer Trialists‘ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717CrossRef
3.
Zurück zum Zitat Aapro MS, Cameron DA, Pettengell R et al. (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42: 2433–2453PubMedCrossRef Aapro MS, Cameron DA, Pettengell R et al. (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42: 2433–2453PubMedCrossRef
4.
Zurück zum Zitat Appelbaum FR, Gundacker H et al. (2006) Age and acute myeloid leukemia. Blood 107: 3481–3485PubMedCrossRef Appelbaum FR, Gundacker H et al. (2006) Age and acute myeloid leukemia. Blood 107: 3481–3485PubMedCrossRef
5.
Zurück zum Zitat Bacher U, Haferlach C et al. (2008) Prognostic relevance of FLT3-TKD mutations in AML: the combination matters – an analysis of 3082 patients. Blood 111: 2527–2537PubMedCrossRef Bacher U, Haferlach C et al. (2008) Prognostic relevance of FLT3-TKD mutations in AML: the combination matters – an analysis of 3082 patients. Blood 111: 2527–2537PubMedCrossRef
6.
Zurück zum Zitat Bauer AW (2003) Futility-Debatte in der Onkologie. Onkologe 9: 1325–1334CrossRef Bauer AW (2003) Futility-Debatte in der Onkologie. Onkologe 9: 1325–1334CrossRef
7.
Zurück zum Zitat Bennett CL, Silver SM et al. (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299: 914–924PubMedCrossRef Bennett CL, Silver SM et al. (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299: 914–924PubMedCrossRef
8.
Zurück zum Zitat Brust-Zentrum W (2007) Jahresauswertung Benchmarking Brustzentren WBC. W. W. B.-Z. GmbH Brust-Zentrum W (2007) Jahresauswertung Benchmarking Brustzentren WBC. W. W. B.-Z. GmbH
9.
Zurück zum Zitat Chapman JA, Meng D et al. (2008) Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100: 252–260PubMedCrossRef Chapman JA, Meng D et al. (2008) Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100: 252–260PubMedCrossRef
10.
Zurück zum Zitat Elkin EB, Hurria A et al. (2006) Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 24: 2757–2764PubMedCrossRef Elkin EB, Hurria A et al. (2006) Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 24: 2757–2764PubMedCrossRef
11.
Zurück zum Zitat Engel J, Nagel G et al. (2002) Primary breast cancer therapy in six regions of Germany. Eur J Cancer 38: 578–585PubMedCrossRef Engel J, Nagel G et al. (2002) Primary breast cancer therapy in six regions of Germany. Eur J Cancer 38: 578–585PubMedCrossRef
12.
Zurück zum Zitat Etienne A, Esterni B et al. (2007) Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 109: 1376–1383PubMedCrossRef Etienne A, Esterni B et al. (2007) Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 109: 1376–1383PubMedCrossRef
13.
Zurück zum Zitat Extermann M, Aapro M et al. (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55: 241–252PubMedCrossRef Extermann M, Aapro M et al. (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55: 241–252PubMedCrossRef
14.
Zurück zum Zitat Falini B, Mecucci C et al. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352: 254–266PubMedCrossRef Falini B, Mecucci C et al. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352: 254–266PubMedCrossRef
15.
Zurück zum Zitat Friedrich C, Kolb G et al. (2003) Comprehensive geriatric assessment in the elderly cancer patient. Onkologie 26: 355–360PubMedCrossRef Friedrich C, Kolb G et al. (2003) Comprehensive geriatric assessment in the elderly cancer patient. Onkologie 26: 355–360PubMedCrossRef
16.
Zurück zum Zitat Giordano SH, Duan Z et al. (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24: 2750–2756PubMedCrossRef Giordano SH, Duan Z et al. (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24: 2750–2756PubMedCrossRef
17.
Zurück zum Zitat Giordano SH, Hortobagyi GN (2008) Time to remove the subspecialty blinders: breast cancer does not exist in isolation. J Natl Cancer Inst 100: 230–231PubMedCrossRef Giordano SH, Hortobagyi GN (2008) Time to remove the subspecialty blinders: breast cancer does not exist in isolation. J Natl Cancer Inst 100: 230–231PubMedCrossRef
18.
Zurück zum Zitat Grimwade D, Walker H et al. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98: 1312–1320PubMedCrossRef Grimwade D, Walker H et al. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98: 1312–1320PubMedCrossRef
19.
Zurück zum Zitat Grothey A, Kellermann L et al. (2002) Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms. Med Klin 97: 270–277CrossRef Grothey A, Kellermann L et al. (2002) Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms. Med Klin 97: 270–277CrossRef
20.
Zurück zum Zitat Jessup JM, Stewart A et al. (2005) Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 294: 2703–2711PubMedCrossRef Jessup JM, Stewart A et al. (2005) Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 294: 2703–2711PubMedCrossRef
21.
Zurück zum Zitat Kuderer NM, Dale DC et al. (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106: 2258–2266PubMedCrossRef Kuderer NM, Dale DC et al. (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106: 2258–2266PubMedCrossRef
22.
Zurück zum Zitat Leith CP, Kopecky KJ et al. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89: 3323–3329PubMed Leith CP, Kopecky KJ et al. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89: 3323–3329PubMed
23.
Zurück zum Zitat Lowenberg B, Zittoun R et al. (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 7: 1268–1274PubMed Lowenberg B, Zittoun R et al. (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 7: 1268–1274PubMed
24.
Zurück zum Zitat Lyman GH (1998) Essentials of clinical decision making: a new way to think about cancer and aging. In: Balducci L, Lyman GH, Ershler W (eds) Comprehensive geriatric oncology. Harwood, Amsterdam Lyman GH (1998) Essentials of clinical decision making: a new way to think about cancer and aging. In: Balducci L, Lyman GH, Ershler W (eds) Comprehensive geriatric oncology. Harwood, Amsterdam
25.
Zurück zum Zitat Morris M, Platell C et al. (2007) Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer 96: 701–707PubMedCrossRef Morris M, Platell C et al. (2007) Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer 96: 701–707PubMedCrossRef
26.
Zurück zum Zitat Muss HB, Biganzoli L et al. (2007) Adjuvant therapy in the elderly: making the right decision. J Clin Oncol 25: 1870–1875PubMedCrossRef Muss HB, Biganzoli L et al. (2007) Adjuvant therapy in the elderly: making the right decision. J Clin Oncol 25: 1870–1875PubMedCrossRef
27.
Zurück zum Zitat Nagel G, Wedding U et al. (2004) The impact of comorbidity on the survival of postmenopausal women with breast cancer. J Cancer Res Clin Oncol 130: 664–670PubMedCrossRef Nagel G, Wedding U et al. (2004) The impact of comorbidity on the survival of postmenopausal women with breast cancer. J Cancer Res Clin Oncol 130: 664–670PubMedCrossRef
28.
Zurück zum Zitat Pinquart M, Hoffken K et al. (2007) Social support and survival in patients with acute myeloid leukaemia. Support Care Cancer 15: 81–87PubMedCrossRef Pinquart M, Hoffken K et al. (2007) Social support and survival in patients with acute myeloid leukaemia. Support Care Cancer 15: 81–87PubMedCrossRef
29.
Zurück zum Zitat Saarni SI, Halila R et al. (2008) Ethically problematic treatment decisions in different medical specialties. J Med Ethics 34: 262–267PubMedCrossRef Saarni SI, Halila R et al. (2008) Ethically problematic treatment decisions in different medical specialties. J Med Ethics 34: 262–267PubMedCrossRef
30.
Zurück zum Zitat Sargent DJ, Patiyil S et al. (2007) End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 25: 4569–4574PubMedCrossRef Sargent DJ, Patiyil S et al. (2007) End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 25: 4569–4574PubMedCrossRef
31.
Zurück zum Zitat Schairer C, Mink PJ et al. (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96: 1311–1321PubMedCrossRef Schairer C, Mink PJ et al. (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96: 1311–1321PubMedCrossRef
32.
Zurück zum Zitat Scholl S, Theuer C et al. (2008) Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. Eur J Haematol 80: 208–215PubMedCrossRef Scholl S, Theuer C et al. (2008) Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. Eur J Haematol 80: 208–215PubMedCrossRef
33.
Zurück zum Zitat Schwartz LM, Woloshin S et al. (1999) Risk communication in clinical practice: putting cancer in context. J Natl Cancer Inst Monogr 25: 124–133PubMed Schwartz LM, Woloshin S et al. (1999) Risk communication in clinical practice: putting cancer in context. J Natl Cancer Inst Monogr 25: 124–133PubMed
34.
Zurück zum Zitat Silvestri G, Pritchard R et al. (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317: 771–775PubMed Silvestri G, Pritchard R et al. (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317: 771–775PubMed
35.
Zurück zum Zitat Slevin ML, Stubbs L et al. (1990) Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 300: 1458–1460PubMedCrossRef Slevin ML, Stubbs L et al. (1990) Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 300: 1458–1460PubMedCrossRef
36.
Zurück zum Zitat Smith TJ, Khatcheressian J et al. (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24: 3187–3205PubMedCrossRef Smith TJ, Khatcheressian J et al. (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24: 3187–3205PubMedCrossRef
37.
Zurück zum Zitat Tilly H, Castaigne S et al. (1990) Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 8: 272–279PubMed Tilly H, Castaigne S et al. (1990) Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 8: 272–279PubMed
38.
Zurück zum Zitat Wedding U, Rohrig B et al. (2006) Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol 132: 665–671PubMedCrossRef Wedding U, Rohrig B et al. (2006) Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol 132: 665–671PubMedCrossRef
39.
Zurück zum Zitat Welch HG, Albertsen PC et al. (1996) Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med 124: 577–584PubMed Welch HG, Albertsen PC et al. (1996) Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med 124: 577–584PubMed
Metadaten
Titel
Übertherapie in der Onkologie: Wann ist weniger mehr?
verfasst von
Dr. U. Wedding
J.G. Meran
K. Höffken
Publikationsdatum
01.07.2008
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 7/2008
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-008-1415-0

Weitere Artikel der Ausgabe 7/2008

Die Onkologie 7/2008 Zur Ausgabe

Neu im Fachgebiet Onkologie

Die beste Jahreszeit für eine Krebsimmuntherapie

16.07.2024 Onkologische Immuntherapie Nachrichten

Die Wirksamkeit von Checkpointhemmern scheint klinisch relevanten saisonalen Schwankungen zu unterliegen. Patienten mit fortgeschrittenem nichtkleinzelligem Lungenkarzinom etwa hatten das beste Outcome, wenn die PD-1-Inhibitor-Infusionen in den Wintermonaten starteten.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

S3-Leitlinie Endometriumkarzinom aktualisiert

15.07.2024 Endometriumkarzinom Nachrichten

Die angepasste Version der S3-Leitlinie Endometriumkarzinom enthält unter anderem Empfehlungen zu Risikofaktoren, wie der Hormonersatztherapie, sowie darüber, wann eine vaginale Brachytherapie und wann eine Perkutanbestrahlung angebracht ist.

Warum junge Brustkrebspatientinnen die endokrine Therapie absetzen

15.07.2024 Mammakarzinom Nachrichten

Bei jungen Brustkrebspatientinnen ist die Wahrscheinlichkeit groß, dass sie eine adjuvante endokrine Therapie vorzeitig absetzen. In einer europäischen Kohorte wurden dafür zwei Risikofaktoren identifiziert, die bei der Behandlung berücksichtigt werden sollten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.